China Medical System （867.HK） Reincluded in S&P Global Sustainability Yearbook （China Edition） and Maintained MSCI ESG “AA” Rating
July 16, 2024 07:53 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, July 16, 2024 (GLOBE NEWSWIRE) -- In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and...
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
June 25, 2024 06:26 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of...
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
June 18, 2024 06:27 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA...
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
April 23, 2024 09:46 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is...
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
April 01, 2024 08:30 ET
|
China Medical System Holdings Ltd.
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo...
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
March 27, 2024 22:09 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013...
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®
February 03, 2024 20:00 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned...
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
January 02, 2024 01:33 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited...
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
December 13, 2023 03:13 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Innovative drugs VALTOCO (Diazepam Nasal Spray)，ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly...
China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China
December 04, 2023 08:28 ET
|
China Medical System Holdings Ltd.
SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new...